CAPABILITY STATEMENT

HDmedical

www.HDmedical.org

CORE COMPETENCIES

Applications

Trauma

Neuro-rehab

Field Hospitals

Tracheostomies

Post-traumatic stress

Feeding tubes

Critically III

Intubated

Delirium

Confused

Dementia

Hospice

Nursing Home

Med-evac transport

Marie T. Pavini MD, FCCM, FCCP mpavini@HDmedical.org (802) 821-1002

EXERSIDES® REFRAINT®: THE WRIST RESTRAINT REPLACEMENT

Critical Care physician Marie T. Pavini founded HD*medical* in Vermont with the EXERSIDES® REFRAINT®, a vital replacement of wrist restraints for patients with vital medical equipment.

Dr. Pavini knew there was something inherently wrong with replacing a smaller patient harm with a larger one. At one time, securing vital medical equipment to a patient required restraint and sedation, causing delirium, muscle wasting, hypotension, and PTSD. Return to function was markedly prolonged both acutely and long-term. Now, by securing tubes and lines in a way that allows safe freedom of movement, patients and casualties require much less or no sedation allowing faster transition to improved cognition, better opportunity for assessment and treatment of pain, brain-muscle connection from the earliest moment, and faster rehabilitation and return to duty. Offering 'Least Restraint Necessary', the EXERSIDES® REFRAINT®, a multi-level protective Physical and Chemical Restraint Alternative for use from ICU to ward to rehab to home is designed to preserve physical and cognitive function. Get them back out there faster and better!

DIFFERENTIATORS

- Protects vital tubes from moving hand **Physical Restraint Alternative** Mitigates risk of post-traumatic stress by:
 - **Early Mobility**
 - **Sedation Minimization**
 - Freedom
 - More respect
 - Multiple levels: liberal to strict
 - Wrist/hand visible and safely available for:
 - IV placement and integrity
 - **Arterial lines**
 - Pulse oximeters
 - Capillary refill & Glucose checks
 - Holding hands and objects
 - Mitigates muscle wasting
 - Mitigates risk of pressure ulcers
 - > CMS compliance: Least Restrictive Intervention

PAST PERFORMANCE

- 2016: \$25k NIH Rehabilitation sub-award grant for prototype R&D
- 2017: Pilot Study: Single-center clinical trial
- 2018-2022: \$1.86M **NIH** award for multi-site Phase I+II clinical trials
- 2019: FDA registered. ISO-13485 compliance. Alowance of Patents.
- 2020: \$375k NIH Administrative Supplement award manufacturing
- 2021: \$3.42M NIH CRP award for commercialization
- 2023: Launch Robley Rex VA hospital and Mayo Clinic agreements

CAGE

7V3G0

DUNS

080649279

WOSB



WOSB CERTIFIED

Hubzone

